1. Exercise-induced bronchoconstriction in children: Montelukast attenuates the immediate-phase and late-phase responses 
Raul E. Melo, MD, Dirceu Solé, MD, Charles K. Naspitz, MD 
Journal of Allergy and Clinical Immunology 
Volume 111, Issue 2, Pages (February 2003)
DOI: /mai
Copyright © 2003 Mosby, Inc. Terms and Conditions

2. Fig. 1
Study diagram. A group of 88 asthmatic children underwent exercise challenges for selecting those with EIB (*) , and of those, 28 patients had a positive challenge result. Twenty-four patients returned for a second challenge 1 week after placebo treatment (#) , and of those, 22 had reproducible challenges. The 22 patients with reproducible challenges were evaluated further and underwent third and fourth challenges. MK, Montelukast.
Journal of Allergy and Clinical Immunology  , DOI: ( /mai )
Copyright © 2003 Mosby, Inc. Terms and Conditions

3. Fig. 2
Baseline values and decreases of FEV1 after exercise challenge on the screening day. No significant correlation was observed between baseline FEV1 values and FEV1 decreases after exercise challenge on the screening day (Spearman correlation test [r s] = 0.08). Data are provided on 88 asthmatic children.
Journal of Allergy and Clinical Immunology  , DOI: ( /mai )
Copyright © 2003 Mosby, Inc. Terms and Conditions

4. Fig. 3
Mean changes of FEV1 from baseline at different challenge days. FEV1 decreases were significantly diminished after montelukast treatment compared with after placebo at 0, 5, 10, 15, 30, and 60 minutes after exercise (*) . Comparing changes in FEV1 on the control, montelukast, and placebo days, there were no significant differences between the control and montelukast days at 0, 15, 30, 60, 120, 180, 360, and 480 minutes after exercise, and FEV1 decreases were greater on the placebo day compared with on the control and montelukast days at 0, 15, 30, and 60 minutes. At 5 and 10 minutes, FEV1 decreases were significantly greater on the placebo day compared with on the montelukast day and greater on the montelukast day compared with on the control day (P < .05, Friedman test). MK, Montelukast.
Journal of Allergy and Clinical Immunology  , DOI: ( /mai )
Copyright © 2003 Mosby, Inc. Terms and Conditions

5. Fig. 4
Mean changes of FEV1 from baseline in patients with reproducible dual-phase responses to exercise (n = 5) at different challenge days. MK, Montelukast.
Journal of Allergy and Clinical Immunology  , DOI: ( /mai )
Copyright © 2003 Mosby, Inc. Terms and Conditions

6. Fig. 5
FEV1 maximum percentage decreases after exercise challenge in patients treated with placebo and montelukast for 1 week (n = 22). The same degree of protection with montelukast was observed regardless of the use of inhaled corticosteroids (ICS) .
Journal of Allergy and Clinical Immunology  , DOI: ( /mai )
Copyright © 2003 Mosby, Inc. Terms and Conditions